

Dr. Falk Pharma GmbH

Certificate of Analysis

Product:

Salofalk 500 mg suppositories

Batch No .:

200173A

Manufacturing date:

02.2020

Expiry date:

02.2023

Production site:

Vifor AG, Zweigniederlassung Medichemie Ettingen

Brühlstrasse 50 4107 Ettingen Switzerland

API; Batch No.:

6156

Test	Specification		Result
Appearance	white to cream-coloured torpedo shaped suppositories, even consistency and undamaged smooth surface		conforms
Colour of solution (Ph. Eur. 2.2.2)	not more than BY ₃		BY ₆
Uniformity of mass (Ph. Eur. 2.9.5)	≥ 18/20: mean value ± 5 % 20/20: mean value ± 10 % none: mean value ± more than 10 %		conforms conforms
Disintegration time (Ph. Eur. 2.9.2)	≤ 25 min		7 min.
Identification (UV)	UV-spectrum of reference solution corresponds to UV-spectrum of sample solution		conforms
Purity * (HPLC)	4-aminophenol 2,5-dihydroxybenzoic acid Any unspecified degradation product Total degradation products	≤ 0.1 % ≤ 0.1 % ≤ 0.1 % ≤ 0.3 %	not determined not determined not determined not determined
Assay (UV)	475-525 mg 5-ASA / suppository (95-105 %)		501 mg/Supp. (100 %)
Microbiological quality (Ph. Eur. 2.6.12/2.6.13)	Total viable aerobic count: Bacteria ≤ 10³ CFU/g Fungi ≤ 10² CFU/g E. coli none/g (according to Ph. Eur. 5.1.4, category 3	a)	< 10 CFU/g < 10 CFU/g absent

^{*} Purity testing is performed in frame of a quality monitoring every 10th batch, at least twice a year

Remarks: We herewith certify that this product is produced according to	GM	Į
---	----	---

Result:

approved

not approved

Freiburg,

08. APR. 2020

Qualified Person - 79



Dr. Falk Pharma GmbH

Batch Certificate

Name of product, strength, dosage form:

Salofalk 500mg Suppositories

Packaging size and type:

5 Suppositories

Importing country:

Chile

Marketing authorisation number:

F-9448/16

Batch number:

200173A

Date of manufacture:

02,2020

Expiry date:

02.2023

Manufacturing site:

Vifor SA, Zweigniederlassung Medichemie Ettingen

Brühlstrasse 50 4107 Ettingen Switzerland

Certificate of GMP Compliance:

GMPE-CH-1000874 (Vifor Ettingen)

Results of analysis:

See CoA attached

Comments:

Certification statement:

I hereby certify that the above information is authentic and accurate. This batch of product has been manufactured, including packaging/labelling and quality control at the above mentioned site in full compliance with the GMP requirements of the local Regulatory Authority and with the specifications in the Marketing Authorisation of the importing country. The batch processing, packaging and analysis records were reviewed and found to be in compliance with GMP.

Dr. Falk Pharma GmbH Qualified Person

Dr. Thomas Fingerhut

bet.

Dr. Thomas Uhlmann Dr. Rudolf Wilhelm Date of signature.